Quarterly report pursuant to Section 13 or 15(d)

4. Significant Strategic Drug Development Collaborations

4. Significant Strategic Drug Development Collaborations	3 Months Ended
Mar. 31, 2015
Research and Development [Abstract]
Significant Strategic Drug Development Collaborations	The Company has entered into various research, development, license and supply agreements with Baxter Healthcare SA (“Baxter SA”) and Baxter Healthcare Corporation (together referred to as “Baxter”), SynBio LLC (“SynBio”), Serum Institute of India (“Serum Institute”) and OJSC Pharmsynthez (“Pharmsynthez”). The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through March 31, 2015. No amounts were recognized as revenue related to these agreements during the three months ended March 31, 2015 or 2014.

4. Significant Strategic Drug Development Collaborations

3 Months Ended

Mar. 31, 2015

Significant Strategic Drug Development Collaborations

The Company has entered into various research, development, license and supply agreements with Baxter Healthcare SA (“Baxter SA”) and Baxter Healthcare Corporation (together referred to as “Baxter”), SynBio LLC (“SynBio”), Serum Institute of India (“Serum Institute”) and OJSC Pharmsynthez (“Pharmsynthez”). The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through March 31, 2015. No amounts were recognized as revenue related to these agreements during the three months ended March 31, 2015 or 2014.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details